The optimization of recombinant antibody production within Chinese hamster ovary (CHO) cells remains a paramount challenge for the biopharmaceutical industry. Multiple strategies are employed maximize antibody titer, such as process parameter optimization, media optimization, and adoption of perfusion systems. Fine-tuning growth parameters plays